Patents by Inventor Veronica Costa

Veronica Costa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION
    Publication number: 20200057052
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Application
    Filed: October 24, 2019
    Publication date: February 20, 2020
    Inventors: Veronica Costa, Maj Hedtjärn, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
  • Oligonucleotides for inducing paternal UBE3A expression
    Patent number: 10494633
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: December 3, 2019
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Veronica Costa, Maj Hedtjärn, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
  • OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION
    Publication number: 20190310244
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Application
    Filed: April 18, 2019
    Publication date: October 10, 2019
    Inventors: Veronica Costa, Maj HEDTJÄRN, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
  • METHODS FOR DETERMINING THE EFFICACY PROFILE OF A DRUG CANDIDATE
    Publication number: 20190154664
    Abstract: This patent application relates to a method for determining the in vitro efficacy profile of a drug candidate using standardized cell cultures of uniformly distributed differentiated neural cells (NCs) from at least two primate species, wherein the differentiated NC cultures are qualified for high throughput screening based on a dissociation and reseeding step performed on the differentiated NCs. The method includes differentiating human and/or non-human primate neuronal precursor cells (NPCs) to neuronal cells (NCs) followed by dissociating the differentiated NCs from its support and reseeding the differentiated NCs in a high-throughput cell culture format resulting in robust cultures suitable for high-throughput drug screening assays, in particular to screen antisense oligonucleotides.
    Type: Application
    Filed: May 11, 2018
    Publication date: May 23, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Carlo CUSULIN, Veronica COSTA, Marius HOENER, Christoph PATSCH, Eva Christina THOMA
  • STANDARDIZED NEURONAL CELL ASSAYS FROM PRIMATE SPECIES
    Publication number: 20190144824
    Abstract: This patent application relates to a method to generate standardized and robust neuronal cell culture assays from primate species, for example suitable for high-throughput screening of drug candidates. The method includes differentiating human and/or non-human primate neuronal precursor cells (NPCs) to neuronal cells (NCs) and producing uniform NC cultures based on a dissociation and reseeding step performed on the differentiated NCs resulting in robust cultures suitable for high-throughput drug screening assays, in particular to screen antisense oligonucleotides.
    Type: Application
    Filed: May 11, 2018
    Publication date: May 16, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Carlo CUSULIN, Veronica COSTA, Marius HOENER, Christoph PATSCH, Eva Christina THOMA
  • OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION
    Publication number: 20170191064
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Application
    Filed: November 14, 2016
    Publication date: July 6, 2017
    Inventors: Veronica Costa, Maj HEDTJÄRN, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen